Method for detecting botulinum toxin A by combining immunomagnetic bead enrichment with fluorescence immunochromatography

Through immunomagnetic bead enrichment combined with fluorescence immunochromatography detection, the problems of cumbersome operation, high false positive rate and high equipment requirements in type A botulinum toxin detection are solved, and fast and accurate trace detection is achieved, suitable for complex and complex Samples have good application prospects.

CN119001090APending Publication Date: 2024-11-22SHANGHAI INT TRAVEL HEALTH CARE CENT (PORT CLINIC OF SHANGHAI ENTRY-EXIT INSPECTION & QUARANTINE BUREAU) +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411256497.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, the type A botulinum toxin detection method is complicated to operate, has a long test cycle, is prone to false positives, is only suitable for testing when Clostridium botulinum, has a long detection time, high requirements for testing equipment and personnel, and requires huge demands. Database analysis cannot meet the needs of fast, accurate and efficient detection.

Method used

Immunomagnetic bead enrichment combined with fluorescence immunochromatography detection method, carboxylated immunomagnetic beads are coupled to BoNT/A monoclonal antibody, sample enrichment and fluorescence immunochromatography are performed, and results are judged using a portable hypersensitive fluorescence analyzer. .

Benefits of technology

It significantly improves the detection value of the antigen to be tested in the sample, has the advantages of high sensitivity, good accuracy, fast and simple, and is suitable for trace BoNT/A detection in simulated samples such as soil, milk, and serum, reducing interference from complex matrix , improve detection sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119001090A_ABST
    Figure CN119001090A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting botulinum toxin A by combining immunomagnetic bead enrichment with fluorescence immunochromatography, which comprises the following steps: coupling a BoNT / A monoclonal antibody with carboxylated immunomagnetic beads to prepare specific BoNT / A immunomagnetic beads, specifically enriching and detecting target antigens from a sample containing trace BoNT / A, and detecting the BoNT / A immunomagnetic beads by using fluorescence immunochromatography. Dissociating the antigen from the immunomagnetic beads for collecting and capturing the target antigen under certain conditions, and detecting the immunomagnetic beads by combining a lanthanide fluorescence immunochromatography method.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection technology, and in particular to a method for detecting botulinum toxin type A by immunomagnetic bead enrichment combined with fluorescent immunochromatography. Background Art

[0002] Botulinum neurotoxin (BoNT) is a potent exotoxin protein secreted by Clostridium botulinum in an anaerobic environment. It can affect nerve transmission and cause muscle paralysis. It is the most toxic natural protein known in nature. According to the difference in toxin antigenicity, BoNT can be divided into seven subtypes, A to G. Among them, botulinum toxin type A (BoNT / A) is the most toxic. The poisoning characteristics are relaxation paralysis and secretion inhibition, which are specifically manifested as blurred vision, oral and tongue pharyngeal symptoms, dysphagia, dysarthria, limb and respiratory muscle paralysis and other neurological symptoms. Severe cases can lead to respiratory distress and even death. BoNT / A is widely used in the field of beauty and is often illegally imported under the name of "beauty injections". Due to its high toxicity, it is often listed as a potential bioterrorism agent and a lethal biological warfare agent, posing a serious threat to public health and biosafety.

[0003] At present, the commonly used detection methods of BoNT / A mainly include three types of methods, namely, mouse in vivo bioassay, molecular biology, and immunology. Mouse in vivo bioassay is the gold standard for BoNT / A detection. This method is stable and reliable, but the operation is cumbersome, the test cycle is long, and it violates the "3R" principle; molecular biological methods such as real-time fluorescence PCR have high sensitivity and strong specificity, but are prone to false positives, and this method is only suitable for detection when Clostridium botulinum is present; immunological methods such as ELISA have high sensitivity and strong specificity, but the time required is long, the detection equipment and personnel requirements are high, and it is impossible to detect whether the toxin is biologically active; mass spectrometry can also be applied to BoNT / A detection. This method uses botulinum toxin to cut the synthetic peptide substrate and then analyze it through a mass spectrometer. It can be used for toxin typing and toxin activity detection, but this method requires expensive detection equipment, professional detection personnel, and a huge database for analysis, and is not suitable for on-site rapid detection.

[0004] Therefore, seeking a simple, rapid, accurate and efficient detection method is of great significance for the rapid detection of BoNT / A. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the object of the present invention is to provide a method for detecting botulinum toxin type A by immunomagnetic bead enrichment combined with fluorescent immunochromatography, so as to solve the problems in the prior art of botulinum toxin type A detection method, such as cumbersome operation, long test cycle, easy false positive, only applicable to detection when Clostridium botulinum is present, long detection time, high requirements on detection equipment and personnel, and need for huge database for analysis.

[0006] In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0007] The method for detecting botulinum toxin type A by immunomagnetic bead enrichment combined with fluorescent immunochromatography has the following specific steps:

[0008] Step 1: coupling the carboxylated immunomagnetic beads with the BoNT / A monoclonal antibody for later use;

[0009] Step 2: Take 1-50 μg of the carboxylated immunomagnetic beads coupled with BoNT / A monoclonal antibody prepared in step 1 into a container, add the sample treatment solution, vortex and shake to mix thoroughly, collect the magnetic beads by magnetic separation, discard the supernatant, repeat twice, and collect the washed carboxylated immunomagnetic beads;

[0010] Step 3: dilute the sample into the sample treatment solution, vortex and mix, and then centrifuge for 10 minutes; take 2 mL of the supernatant and add it to the container containing the carboxylated immunomagnetic beads coupled to the BoNT / A monoclonal antibody, vortex and mix, and incubate at 37-42°C for 1-2 hours; then let the incubated mixture stand for magnetic separation, discard the supernatant, and add 50 μL of eluent, stand and incubate at room temperature, and add 5 μL of neutralizing solution to the supernatant after magnetic separation; wherein, according to the mass volume ratio, the amount of sample added is 10% (M / V), the eluent is a citric acid aqueous solution with a concentration of 0.3 mol / L; the neutralizing solution is a 0.1 mol / L NaOH solution;

[0011] Step 4: Mix the liquid in step 3 with the sample solution on the reagent card in a mass ratio of 1:1, then add it dropwise to the sample loading hole of the BoNT / A time-resolved fluorescence detection reagent card. Allow the chromatography to react for 10 to 20 minutes, and use a portable high-sensitivity fluorescence analyzer to detect the fluorescence signal and interpret the results.

[0012] Preferably, in step 1, the carboxylated immunomagnetic beads are coupled to the BoNT / A monoclonal antibody using the following steps:

[0013] S1 washing: taking carboxylated magnetic beads and adding MES aqueous solution to wash, collecting the magnetic beads by magnetic separation after washing, and resuspending the magnetic beads in MES aqueous solution; wherein, the concentration of MES in the MES aqueous solution is 0.05 mol / L, and the concentration of the magnetic beads resuspended in MES is 1 mg / 900 μL;

[0014] S2 activation: ultrasonically disperse the magnetic beads prepared in S1, add activation reagents NHS and EDC solution respectively, vortex to mix, and incubate at room temperature for 20 to 30 minutes; magnetically separate and discard the supernatant, add MES to wash the magnetic beads, and then re-dissolve the magnetic beads with MES; wherein, calculated by mass volume ratio, the amount of NHS added is 0.2% (M / V), and the amount of EDC added is 0.2% (M / V).

[0015] S3 coupling: put the MES-reconstituted magnetic beads and BoNT / A monoclonal antibodies treated in S2 into a container, fill up to 500 μL with PBS buffer, mix thoroughly, and couple at 37°C for 2 h; discard the supernatant by magnetic separation, and wash the magnetic beads three times with PBS buffer to remove unbound antibodies; the mass volume ratio of magnetic beads to BoNT / A monoclonal antibodies is 0.5 mg:250 μL; the concentration of BoNT / A monoclonal antibodies is 1 mg / ml;

[0016] S4 blocking: Add the magnetic beads treated with S3 to the blocking solution, mix thoroughly, and invert and block at 37°C for 30 minutes; then, discard the supernatant by magnetic separation, wash the magnetic beads 3 times with PBS buffer, and then resuspend the magnetic beads in PBS buffer and place them at 4°C for use.

[0017] Preferably, in step 1, the particle size of the carboxylated magnetic beads is 0.6-3 μm.

[0018] Preferably, in step 3, the concentration of the eluent is 0.1 to 0.5 mol / mL.

[0019] Preferably, in step 2, the amount of magnetic beads used is 1 to 10 μg.

[0020] Preferably, in step 3, the incubation temperature is 42°C.

[0021] Preferably, in the BoNT / A time-resolved fluorescence detection reagent card, BoNT / A monoclonal antibody 1 labeled with time-resolved fluorescent microspheres is located at the marker pad on the reagent card, and BoNT / A monoclonal antibody 2 is coated at the T-line position of the nitrocellulose membrane.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] 1. The present invention uses carboxylated immunomagnetic beads as carriers, couples BoNT / A monoclonal antibodies to them, further optimizes the process of magnetic bead-coupled antibodies, thereby exploring the best enrichment scheme, and establishing a method for detecting BoNT / A in combination with lanthanide fluorescent immunochromatography. The present invention takes into account the actual detection needs in various fields, can enrich BoNT / A from more complex sample matrices, and provides new technical means for rapid screening and trace detection of BoNT / A.

[0024] 2. The BoNT / A detection method of the present invention, which combines immunomagnetic bead enrichment with fluorescent immunochromatography, can significantly improve the detection value of the antigen to be tested in the sample. It has the advantages of high sensitivity, good accuracy, rapidity and simplicity. It has excellent detection effects on trace BoNT / A in simulated samples such as soil, milk, and serum, and has good application prospects in the detection of BoNT / A. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This graph shows the effect of different carboxylated immunomagnetic bead particle sizes on BoNT / A enrichment.

[0026] Figure 2 Graph showing the effect of eluent concentration on BoNT / A enrichment.

[0027] Figure 3 This graph shows the effect of the amount of carboxylated immunomagnetic beads used on BoNT / A enrichment.

[0028] Figure 4 This is a diagram showing the effect of enrichment temperature on BoNT / A enrichment. DETAILED DESCRIPTION

[0029] The present invention will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the present invention belong to the scope of protection of the present invention.

[0030] Unless otherwise indicated in specific cases in the present invention, the numerical ranges listed herein include the upper and lower limits, and all integers and fractions within the range, and are not limited to the specific values ​​listed when defining the range.

[0031] 1. Method for detecting botulinum toxin type A by immunomagnetic bead enrichment combined with fluorescent immunochromatography

[0032] Step 1: coupling the carboxylated immunomagnetic beads with the BoNT / A monoclonal antibody for later use;

[0033] Step 2: Take 1-50 μg of the carboxylated immunomagnetic beads coupled with BoNT / A monoclonal antibody prepared in step 1 into a container, add the sample treatment solution, vortex and shake to mix thoroughly, collect the magnetic beads by magnetic separation, discard the supernatant, repeat twice, and collect the washed carboxylated immunomagnetic beads;

[0034] Step 3: dilute the sample into the sample treatment solution, vortex and mix, and then centrifuge for 10 minutes; take 2 mL of the supernatant and add it to the container containing the carboxylated immunomagnetic beads coupled to the BoNT / A monoclonal antibody, vortex and mix, and incubate at 37-42° C. for 1-2 hours; then let the incubated mixture stand for magnetic separation, discard the supernatant, and add 50 μL of eluent, stand and incubate at room temperature, and add 5 μL of neutralizing solution to the supernatant after magnetic separation; wherein, based on the volume of the sample treatment solution and calculated according to the mass-to-volume ratio, the amount of sample added is 10% (M / V, mass μg / volume μL), the eluent is a citric acid aqueous solution with a concentration of 0.3 mol / L; the neutralizing solution is a 0.1 mol / L NaOH solution;

[0035] Step 4: Mix the liquid in step 3 with the sample solution on the reagent card in a mass ratio of 1:1, then add it dropwise to the sample well of the BoNT / A time-resolved fluorescence detection reagent card. Allow the chromatography to react for 10 to 20 minutes, and use a portable high-sensitivity fluorescence analyzer to detect the fluorescence signal and interpret the results.

[0036] After in-depth research on the detection method of botulinum toxin type A (BoNT / A), the present invention considers the actual detection needs in various fields and hopes to construct a method that is simple to operate and can quickly detect botulinum toxin type A. Therefore, the present invention considers using a reagent card to detect, but the present invention finds that the BoNT / A time-resolved fluorescence detection reagent card has problems when used for complex sample detection. The prior art pre-treatment method for the sample is to dilute the sample with a reagent extract, and the centrifugal supernatant is added dropwise to the detection card sample well after dilution. However, if the dilution multiple is low, it is difficult to perform normal chromatography on the immunochromatographic test paper card for samples such as soil and skim milk, which will result in invalid detection; if the dilution multiple data is increased, the detection sensitivity will be correspondingly reduced. The present invention considers using magnetic beads for enrichment pre-treatment, using carboxylated immunomagnetic beads as carriers, coupling BoNT / A monoclonal antibodies to them, and further optimizing the process of magnetic bead-coupled antibodies, thereby exploring the best enrichment scheme, and combining lanthanide fluorescent immunochromatography to establish a method for detecting BoNT / A. The present invention takes into account the actual detection needs in various fields, can enrich BoNT / A from relatively complex sample matrices, reduces complex matrix interference, and also greatly improves detection sensitivity, providing a new technical means for rapid screening and trace detection of BoNT / A.

[0037] In some embodiments, in step 1, the carboxylated immunomagnetic beads are coupled to the BoNT / A monoclonal antibody by the following steps:

[0038] S1 washing: taking carboxylated magnetic beads and adding MES aqueous solution to wash, collecting the magnetic beads by magnetic separation after washing, and resuspending the magnetic beads in MES aqueous solution; wherein, the concentration of MES in the MES aqueous solution is 0.05 mol / L, and the concentration of the magnetic beads resuspended in MES is 1 mg / 900 μL;

[0039] S2 activation: ultrasonically disperse the magnetic beads prepared in S1, add solid activation reagents NHS and EDC solution respectively, vortex to mix, and incubate at room temperature for 20 to 30 minutes; magnetically separate and discard the supernatant, add MES to wash the magnetic beads, and then re-dissolve the magnetic beads with MES; wherein, based on the magnetic bead resuspension after ultrasonic treatment, the amount of NHS added is 0.2% (M / V, mass μg / volume μL), and the amount of EDC added is 0.2% (M / V, mass μg / volume μL) calculated according to the mass-to-volume ratio.

[0040] S3 coupling: put the MES-reconstituted magnetic beads and BoNT / A monoclonal antibodies treated in S2 into a container, fill up to 500 μL with PBS buffer, mix thoroughly, and couple at 37°C for 2 h; discard the supernatant by magnetic separation, and wash three times with PBS buffer to remove unbound antibodies; the mass volume ratio of magnetic beads to BoNT / A monoclonal antibodies is 0.5 mg: 250 μL; the concentration of BoNT / A monoclonal antibodies is 1 mg / ml;

[0041] S4 blocking: Add the magnetic beads treated with S3 to the blocking solution, mix thoroughly, and invert and block at 37°C for 30 minutes; then, discard the supernatant by magnetic separation, wash the magnetic beads 3 times with PBS buffer, and then resuspend the magnetic beads in PBS buffer and place them at 4°C for use.

[0042] In some embodiments, in step 1, the particle size of the carboxylated magnetic beads is 0.6 to 3 μm. The particle size of the carboxylated magnetic beads can be 0.6 μm, 1 μm, 3 μm, etc., and all ranges and sub-ranges between the above values. It should be understood that in the embodiments, any of the above ranges can be combined with any other ranges.

[0043] In some embodiments, in step 3, the concentration of the eluent is 0.1 to 0.5 mol / mL. The concentration of the eluent can be 0.1 mol / mL, 0.2 mol / mL, 0.3 mol / mL, 0.4 mol / mL, 0.5 mol / mL, etc., and all ranges and sub-ranges between the above values. It should be understood that, in embodiments, any of the above ranges can be combined with any other ranges.

[0044] In some embodiments, in step 2, the amount of magnetic beads is preferably 1 to 10 μg. The amount of magnetic beads can be 1 μg, 2 μg, 5 μg, 10 μg, 25 μg, 50 μg, etc., and all ranges and sub-ranges between the above values. It should be understood that in the embodiments, any of the above ranges can be combined with any other ranges.

[0045] In some embodiments, in step 3, the incubation temperature is 42°C.

[0046] In some embodiments, in a BoNT / A time-resolved fluorescence detection reagent card, the reagent card adopts the structure of an existing conventional reagent card, and the BoNT / A monoclonal antibody 1 is labeled with time-resolved fluorescent microspheres and is located at the marker pad on the reagent card, and the BoNT / A monoclonal antibody 2 is coated at the T line position of the nitrocellulose membrane. 2. Specific implementation methods

[0048] 1. Instruments and reagents

[0049] High-sensitivity fluorescence analyzer: Chengdu Weirui Biotechnology Co., Ltd.; Mag-12-1-2 magnetic separation rack: Shenzhen Boerxi Technology Development Co., Ltd.; MX-F vortex shaker: Dalong Xingchuang Experimental Instrument (Beijing) Co., Ltd.; TST101A-1 incubator: Chengdu Test Instrument Co., Ltd.; VS-18 rotary incubator: Wuxi Woxin Instrument Co., Ltd.

[0050] BoNT / A time-resolved fluorescence detection reagent card: Chengdu Weirui Biological Co., Ltd.; carboxyl modified magnetic beads: purchased from a company in Chengdu; BoNT / A and its monoclonal antibody: provided by the Academy of Military Sciences of the Chinese People's Liberation Army; 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC), N-hydroxysuccinimide (NHS): purchased from Aladdin. MES (2-(N-morpholino)ethanesulfonic acid): purchased from Sinopharm Chemical Reagent Co., Ltd.

[0051] The sample treatment solution, elution solution, neutralization balance solution, and reagent card loading solution were homemade, and the components are as follows:

[0052] Sample treatment solution: calculated by mass volume percentage (g / mL), disodium hydrogen phosphate dodecahydrate (Na2HPO4·12H2O) (0.364%), NaCl (0.082%), KCl (0.02%), Tween-20 (0.25%), pH (7.4);

[0053] Eluent: 0.1 mol / L citric acid (PH 2.5-3.0);

[0054] Neutralizing solution: 1 mol / L NaOH (PH 8.5);

[0055] Reagent card loading solution: calculated by mass volume percentage (g / mL), Na2HPO4·12H2O (0.364%), K2HPO4·3H2O (0.082%), NaCl (0.8%), KCl (0.02%), Tween-20 (0.25%), PH (7.4).

[0056] 2. Preparation of carboxylated immunomagnetic beads coupled to antibodies

[0057] 1) Washing: Take 1 mg of well-shaken carboxylated magnetic beads and add them to a 2 mL centrifuge tube containing 1 mL of MES to wash the beads; after separation with a magnetic stand, resuspend the beads in 900 μL of MES;

[0058] 2) Activation: The magnetic beads were dispersed by ultrasound, and then solid activation reagents NHS and EDC were added thereto, mixed by vortexing, and fixed in a rotating incubator for incubation at room temperature for 25 min; the supernatant was discarded by magnetic separation, 1 mL of MES was added to wash the magnetic beads, and then 500 μL of MES was added to re-dissolve the magnetic beads; wherein, calculated by mass-to-volume ratio, the amount of NHS added was 0.2% (M / V, mass μg / volume μL), and the amount of EDC added was 0.2% (M / V, mass μg / volume μL).

[0059] 3) Coupling: Take 0.5 mg (250 μL) of activated carboxylated immunomagnetic beads into two 2 mL centrifuge tubes, then add 250 μL of two pre-diluted BoNT / A monoclonal antibodies (the concentration of BoNT / A monoclonal antibodies in the diluted solution is 1 mg / ml), make up to 500 μL with PBS buffer, mix thoroughly with a vortex shaker, fix on a flip incubator, and couple at 37°C for 2 h; magnetic separation discards the supernatant, and wash three times with 500 μL PBS buffer to remove unbound antibodies;

[0060] 4) Blocking: Take 500 μL of magnetic bead blocking solution and add it to the centrifuge tube containing carboxylated immunomagnetic beads, vortex and shake to mix thoroughly, fix it on the flip incubator, and flip and block at 37°C for 30 minutes; magnetic separation discards the supernatant, add 500 μL PBS buffer to wash thoroughly 3 times, and finally add 500 μL PBS buffer to resuspend the magnetic beads and place them at 4°C for use.

[0061] 3. BoNT / A enrichment experiment

[0062] 1) Washing: Take 20 μg of carboxylated immunomagnetic beads coupled with BoNT / A monoclonal antibody into a 5 mL EP tube, add 2 mL of sample treatment solution, vortex and shake to mix thoroughly, place on a magnetic stand to collect the beads, discard the supernatant, repeat the above operation twice, and collect the washed carboxylated immunomagnetic beads;

[0063] 2) BoNT / A extraction and elution: Dilute the sample into the sample treatment solution (the mass μg / volume μL ratio of the sample and the diluent is 10%), vortex to mix, and centrifuge at 4000rpm for 10min. Take 2mL of the supernatant and add it to the EP tube containing carboxylated immunomagnetic beads, vortex to mix, and incubate in a flip incubator at 42°C for 1h. Then, place the BoNT / A-magnetic bead mixture on the magnetic stand for 1min, discard the supernatant, add 50μL of elution solution, incubate at room temperature, and then add 5μL of neutralization solution;

[0064] 3) BoNT / A collection and detection: Take 50 μL of supernatant and 50 μL of reagent card loading solution, vortex and shake to mix thoroughly, then add them dropwise to the loading hole of BoNT / A time-resolved fluorescence detection reagent card, react for 15 minutes, and use a portable high-sensitivity fluorescence analyzer to detect the fluorescence signal and interpret the results.

[0065] 4. Effect of carboxylated immunomagnetic bead size on BoNT / A enrichment

[0066] Activated carboxylated magnetic beads with particle sizes of 0.6 μm, 1 μm, and 3 μm were selected and treated using the coupling step of the present invention to obtain BoNT / A immunomagnetic beads with different particle sizes. 300 μL of immunomagnetic beads with different particle sizes were taken to enrich negative and positive samples, and the test samples were treated to the required concentration by the sample treatment solution, and the enrichment effect was compared by T / C value and discrimination.

[0067] Specific operation: Take 25μL of immunomagnetic beads and add them to 1mL of sample, mix well, and incubate at 42℃ for 1h. Place the BoNT / A-magnetic bead mixture on the magnetic stand for 1min and discard the supernatant. Add 50μL of eluent (0.5M) and incubate at room temperature for 12min. Then place it on the magnetic stand for 1.5min and take the supernatant and add it to 5ul of neutralizing solution. Take 50μL of the mixture to 50μL of the reagent card loading solution, vortex and shake to mix, add it dropwise to the BoNT / A time-resolved fluorescence detection reagent card loading hole, chromatographic reaction for 15min, and use a portable high-sensitivity fluorescence analyzer to detect the fluorescence signal and interpret the results.

[0068] Table 1 Effect of different carboxylated immunomagnetic beads size on BoNT / A enrichment

[0069] Magnetic bead size 0.6μm 1μm 3μm Pre-enrichment test results Positive sample detection value (T / C) 0.7481 0.692 0.5006 0.1859 Negative sample test value (T / C) 0.0218 0.0249 0.0204 0.0221

[0070] From Table 1 and Figure 1It can be seen that the carboxylated immunomagnetic beads with a particle size of 0.6 μm have the best enrichment effect on BoNT / A toxins, and the T / C values ​​of positive samples and negative samples have the highest degree of differentiation. The same antibody was labeled with three different sizes of magnetic beads, and it was found that there was a small effect on the enrichment effect. The smaller the particle size of the magnetic beads, the better the enrichment effect. The main reason for the analysis is that the smaller the microspheres, the larger the specific surface area under the same solid content, so the efficiency of labeling monoclonal antibodies is higher. At the same time, the larger the specific surface area, the greater the probability of binding with the antigen in the liquid, which will improve the enrichment effect.

[0071] 5. Effect of eluent concentration on BoNT / A enrichment

[0072] Take 300 μL of immunomagnetic beads enriched samples for BoNT / A, and the operation steps are consistent with the enrichment operation in Part 4. In order to select the best eluent, the concentration of the eluent was optimized, and 0.1M, 0.2M, 0.3M, 0.4M, and 0.5M eluents were selected to elute the BoNT / A-magnetic bead mixture. The supernatant was taken for magnetic separation and added with neutralizing solution. Finally, 50 μL of the mixture was added to 50 μL of the reagent card loading solution, vortexed and mixed, and then added to the BoNT / A time-resolved fluorescence detection reagent card loading hole. The chromatography reaction lasted for 15 minutes, and the fluorescent signal was detected and the results were interpreted using a portable high-sensitivity fluorescence analyzer. The enrichment effect was compared by T / C value and discrimination.

[0073] Table 2 Effect of eluent concentration on BoNT / A enrichment

[0074] Eluent concentration 0.1M 0.2M 0.3M 0.4M 0.5M Pre-enrichment test results Positive sample detection value (T / C) 0.0721 0.1962 0.7905 0.2991 0.2339 0.2373 Negative sample test value (T / C) 0.023 0.0386 0.035 0.0318 0.0416 0.0229

[0075] From Table 2 and Figure 2 It can be seen that the enrichment effect of BoNT / A toxin is best when the eluent concentration is 0.3M, and the discrimination between the T / C values ​​of positive samples and negative samples is the highest. When using antigen-antibody separation under strong acid conditions, on the one hand, it is necessary to ensure that the antigen is fully eluted under acidic conditions, and at the same time, it is also necessary to ensure the antigen activity of the antigen separated under strong acid. Therefore, the concentration of the antigen eluent has a great influence on the elution of different antigens and antibodies. The optimal condition eluent in the present invention is a 0.3 mol / mL citric acid aqueous solution.

[0076] 6. Effect of the amount of carboxylated immunomagnetic beads used on BoNT / A enrichment

[0077] Take 300 μL of immunomagnetic beads for BoNT / A for sample enrichment, and the operation steps are consistent with the enrichment operation in Part 4. In order to select the optimal amount of carboxylated immunomagnetic beads, 1 μg, 2 μg, 5 μg, 10 μg, 25 μg, and 50 μg of immunomagnetic beads were selected for sample enrichment. After magnetic separation, add 50 μL of eluent (5M) and incubate at room temperature for 12 minutes. After the mixture was placed on the magnetic stand for 1.5 minutes, the supernatant was taken and added to 5 μL of neutralizing solution. Finally, 50 μL of supernatant was added to 50 μL of reagent card loading solution, vortexed and mixed, and added to the BoNT / A time-resolved fluorescence detection reagent card loading hole. The chromatography reaction lasted for 15 minutes, and the fluorescent signal was detected and the results were interpreted using a portable high-sensitivity fluorescence analyzer, and the T / C value and discrimination were compared.

[0078] Table 3 Effect of the amount of carboxylated immunomagnetic beads used on BoNT / A enrichment

[0079]

[0080] From Table 3 and Figure 3 It can be seen that the enrichment effect of BoNT / A toxin is best when the amount of carboxylated immunomagnetic beads used is 2 μg, and the discrimination between the T / C values ​​of positive samples and negative samples is the highest. The present invention found that in the enrichment experiment, the use of too much coupled antibody microspheres will reduce the enrichment effect. The reason for this may be that excessive antibodies will cause the antigen to form a double antibody conjugate, which is more difficult to elute in the later elution step, resulting in a poor elution effect.

[0081] 7. Effect of enrichment temperature on BoNT / A enrichment

[0082] In order to select the best enrichment temperature, the samples were enriched with magnetic beads at room temperature, 37°C and 42°C respectively. The operation steps were consistent with the enrichment operation in Part 4. Finally, 50 μL of supernatant was added to 50 μL of reagent card loading solution, vortexed and mixed, and then added to the sample well of BoNT / A time-resolved fluorescence detection reagent card. The chromatography reaction lasted for 15 minutes. The fluorescent signal was detected and the results were interpreted using a portable high-sensitivity fluorescence analyzer, and the T / C values ​​and discrimination were compared. The experimental results are shown in Table 4 and Figure 4 .

[0083] Table 4 Effect of enrichment temperature on BoNT / A enrichment

[0084] Enrichment temperature (unit: ℃) normal temperature 37 42 Positive sample detection value (T / C) 0.6316 0.7819 0.9641 Negative sample test value (T / C) 0.0236 0.0213 0.0168

[0085] Temperature affects the antigen-antibody reaction rate during enrichment. Within a certain range, the enrichment effect increases with increasing temperature. In order to achieve a better enrichment effect in the shortest possible time, the optimal condition of the present invention is enrichment at 42°C.

[0086] 8. Complex matrix sample simulation experiment

[0087] In order to preliminarily verify the application of carboxylated immunomagnetic beads in the actual scenario of BoNT / A toxin detection and compare the matrix interference and sensitivity before and after enrichment, the present invention used soil, skimmed milk powder and serum containing trace amounts of BoNT / A as complex matrix samples for simulation experiments.

[0088] The present invention prepares two groups of test simulation samples, one group of diluents and negative soil, skim milk, serum are shaken and mixed at a mass ratio of 5:1, and then centrifuged to take the supernatant of three matrix extracts for standby use, which is the negative group. Another group of diluents and positive soil, skim milk, and serum with added standard substances are shaken and mixed at a mass ratio of 5:1, and then centrifuged to take the supernatant of three matrix extracts for standby use, which is the positive group. Directly take 80 μL of the negative group and the positive group respectively and drop them onto the time-resolved immunochromatographic detection reagent card, and after chromatography for 15 minutes according to the reagent card detection operating instructions, the fluorescent signal is detected using a portable high-sensitivity fluorescence analyzer. At the same time, the negative group and the positive group are enriched according to the above optimized enrichment conditions and then dropped onto the time-resolved immunochromatographic detection card for detection. Compare the two test results.

[0089] The test results of the two groups of simulated negative and positive samples are shown in Table 5. The skim milk sample was invalid before enrichment using the high-sensitivity fluorescence detection card. The soil and serum detection sensitivity was low, and the discrimination compared with the negative group was only about 2. After enrichment, BoNT / A can be clearly detected using the high-sensitivity fluorescence detection card. The discrimination in soil matrix samples increased by about 4 times, skim milk changed from invalid to high-discrimination samples, and the serum discrimination increased by about 6 times.

[0090] Table 5 Complex matrix sample simulation experiment

[0091]

[0092] When the time-resolved fluorescent immunochromatographic test card detects BoNT / A in soil, skim milk, and serum samples, the simplest pre-treatment method is to dilute the soil, skim milk, and serum with a reagent extract, and then drip the centrifuged supernatant after dilution into the sample well of the test card. Since the soil skim milk has a low dilution multiple, it is difficult to perform normal chromatography on the immunochromatographic test paper card, resulting in invalid detection. If the dilution multiple data is increased, the detection sensitivity will be reduced accordingly, which is the bottleneck problem of time-resolved chromatography test paper card detection. The method described in the present invention is used to perform magnetic bead enrichment pre-treatment, and the detection antigen is extracted from the sample treated with the same dilution multiple, which reduces the complex matrix interference and greatly improves the detection sensitivity.

[0093] The results showed that 1 μg of carboxylated immunomagnetic beads with a particle size of 0.6 μm were coupled with BoNT / A monoclonal antibodies, and BoNT / A antigens were enriched at 42°C, followed by antigen elution with an eluent having a concentration of 5 M. At this time, the antigen enrichment effect of BoNT / A was optimal. The present invention utilizes immunomagnetic bead enrichment and lanthanide fluorescent immunochromatography technology to jointly detect BoNT / A, and can detect target antigens in samples containing trace amounts of BoNT / A. This method has high specificity, good repeatability, high sensitivity, simplicity and rapidity, and has good application prospects in large-scale rapid detection of BoNT / A.

[0094] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the technical solution. Those skilled in the art should understand that those modifications or equivalent substitutions of the technical solution of the present invention that do not depart from the purpose and scope of the technical solution should be included in the scope of the claims of the present invention.

Claims

1. A method for detecting botulinum toxin type A by immunomagnetic bead enrichment combined with fluorescent immunochromatography, characterized in that: The specific steps are as follows: Step 1: coupling the carboxylated immunomagnetic beads with the BoNT / A monoclonal antibody for later use; Step 2: Take 1-50 μg of the carboxylated immunomagnetic beads coupled with BoNT / A monoclonal antibody prepared in step 1 into a container, add the sample treatment solution, vortex and shake to mix thoroughly, collect the magnetic beads by magnetic separation, discard the supernatant, repeat twice, and collect the washed carboxylated immunomagnetic beads; Step 3: Dilute the sample into the sample treatment solution, vortex and mix, and then centrifuge for 10 minutes; take 2 mL of the supernatant and add it to the container containing the carboxylated immunomagnetic beads coupled to the BoNT / A monoclonal antibody, vortex and mix, and incubate at 37-42°C for 1-2 hours; then let the incubated mixture stand for magnetic separation, discard the supernatant, add 50 μL of eluent, stand and incubate at room temperature, collect the supernatant by magnetic separation, and add 5 μL of neutralizing solution; wherein, the amount of sample added is 10% calculated by mass volume ratio; the eluent is a citric acid aqueous solution, and its concentration does not exceed 0.5 mol / L; the neutralizing solution is a 0.1 mol / L NaOH solution; Step 4: Mix the liquid in step 3 with the sample solution on the reagent card in a mass ratio of 1:1, then add it dropwise to the sample well of the BoNT / A time-resolved fluorescence detection reagent card. Allow the chromatography to react for 10 to 20 minutes, and use a portable high-sensitivity fluorescence analyzer to detect the fluorescence signal and interpret the results.

2. The method according to claim 1, characterized in that: In step 1, carboxylated immunomagnetic beads are coupled to BoNT / A monoclonal antibodies by the following steps: S1 washing: taking carboxylated magnetic beads and adding MES aqueous solution to wash, collecting the magnetic beads by magnetic separation after washing, and resuspending the magnetic beads in MES aqueous solution; wherein, the concentration of MES in the MES aqueous solution is 0.05 mol / L, and the concentration of the magnetic beads resuspended in MES is 1 mg / 900 μL; S2 activation: ultrasonically disperse the magnetic beads prepared in S1, add solid activation reagents NHS and EDC respectively, vortex to mix, and incubate at room temperature for 20 to 30 minutes; magnetically separate and discard the supernatant, add MES to wash the magnetic beads, and then re-dissolve the magnetic beads with MES; wherein, calculated by mass volume ratio, the amount of NHS added is 0.2%, and the amount of EDC added is 0.2%; S3 coupling: put the MES-reconstituted magnetic beads and BoNT / A monoclonal antibodies treated in S2 into a container, fill up to 500 μL with PBS buffer, mix thoroughly, and couple at 37°C for 2 h; discard the supernatant by magnetic separation, and wash the magnetic beads three times with PBS buffer to remove unbound antibodies; the mass volume ratio of magnetic beads to BoNT / A monoclonal antibodies is 0.5 mg:250 μL; the concentration of BoNT / A monoclonal antibodies is 1 mg / ml; S4 blocking: Add the magnetic beads treated with S3 to the blocking solution, mix thoroughly, and invert and block at 37°C for 30 minutes; then, discard the supernatant by magnetic separation, wash the magnetic beads 3 times with PBS buffer, and then resuspend the magnetic beads in PBS buffer and place them at 4°C for use.

3. The method according to claim 1, characterized in that: In step 1, the particle size of the carboxylated magnetic beads is 0.6 to 3 μm.

4. The method according to claim 1, characterized in that: In step 3, the concentration of the eluent is 0.1 to 0.5 mol / mL.

5. The method according to claim 1, characterized in that: In step 2, the amount of magnetic beads used is 1 to 10 μg.

6. The method according to claim 1, characterized in that: In step 3, the incubation temperature is 42°C.

7. The method according to claim 1, characterized in that: In the BoNT / A time-resolved fluorescence detection reagent card, BoNT / A monoclonal antibody 1 is labeled with time-resolved fluorescent microspheres and is located at the marker pad on the reagent card, and BoNT / A monoclonal antibody 2 is coated at the T-line position of the nitrocellulose membrane.